ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−1.25%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.67
From 52W high−99.68%
Volume142616.00
Market cap$2.59M
P/E (TTM)—
P/S (TTM)4.0x
Div yield—
Key dataSep 18, 2026
Open
$0.67
From 52W high
−99.68%
Volume
142616.00
Market cap
$2.59M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
42.5
MomentumView details →
1D Return
−1.25%
YTD Return
−99.16%
SummaryUpdated Jun 1, 2026
Onconetix, Inc. (NASDAQ:ONCO) is a biotechnology and pharmaceutical company founded in 2018 and headquartered in Cincinnati, Ohio. Originally incorporated as Blue Water Biotech, Inc., the company changed its name to Onconetix in December 2023. The company went public in February 2022 and focuses on developing and commercializing transformational therapies to address various health challenges worldwide. Onconetix operates in the biotechnology sector with a dual focus on commercializing existing FDA-approved treatments and developing innovative vaccine candidates for infectious diseases.
Similar companies
Latest newsMore news →
Onconetix, Inc. agreed to lend Realbotix, LLC up to $5.0 million under an unsecured grid promissory note, with $2.5 million advanced initially, maturing September 11, 2027.6d agoRealbotix LLC, a wholly owned subsidiary of Realbotix Corp., entered into an unsecured bridge loan facility with Onconetix, Inc. in connection with their proposed merger.6d agoOnconetix entered into a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.17d ago